
## **ESMO 2023 INDUSTRY SATELLITE SYMPOSIUM**



# **Keeping the Outcome in Mind**

Applying Best Practices for Managing HR+/HER2- EBC at High Risk of Recurrence

SATURDAY, 21 OCTOBER 2023 | 13:00-14:30 CEST

VALENCIA AUDITORIUM, HALL 10, IFEMA MADRID, MADRID, SPAIN

Medscape Oncology

#### **MODERATOR**



Sara Hurvitz, MD
Professor of Medicine
Head, Division of Hematology and Oncology
Senior Vice President,
Clinical Research Division
Department of Medicine, UW Medicine
Fred Hutchinson Cancer Center
Seattle, Washington, United States

### **PANELISTS**



Erika Hamilton, MD
Director, Breast Cancer & Gynecologic Cancer
Research Program
Principal Investigator
Sarah Cannon Cancer Institute
Nashville, Tennessee, United States



Stephen R.D. Johnston, MA, FRCP, PhD
Professor of Breast Cancer Medicine
Head of Medical Oncology
Consultant Medical Oncologist
Head of The Breast Unit
The Royal Marsden NHS Foundation Trust &
The Institute of Cancer Research
London, United Kingdom



Patrick Neven, MD, PhD
Professor
Universitair Ziekenhuis Leuven Breast Centre
Leuven, Belgium

#### **AGENDA**

13:00–13:05 Welcome and Introduction Sara Hurvitz, MD

#### 13:05-13:20

Keeping the Outcome in Mind: The Patient With HR-Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence Patrick Neven. MD

#### 13:20-13:40

Latest Developments for Oral Adjuvant Therapy: Analyzing the Latest Data, Guideline Recommendations and Best Practices

Stephen R.D. Johnston, MD, PhD

#### 13:40-14:00

Managing the Patient at Risk: Which Patients Will Benefit From Adjuvant Oral Anti-Cancer Therapies?

Sara Hurvitz, MD Patrick Neven, MD

#### 14:00-14:15

How to Approach Nonadherence in Practice: Clinical Pearls for the Multidisciplinary Team
Erika Hamilton, MD

14:15–14:30 Q&A Session All Speakers

THIS CONTENT IS NOT INTENDED FOR HCPS IN SPAIN OR AVAILABLE FOR CREDIT FOR SPANISH HCPS.

